Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

175 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinicopathological characteristics and outcome of 31 patients with ETV6-NTRK3 fusion gene confirmed (mammary analogue) secretory carcinoma of salivary glands.
Boon E, Valstar MH, van der Graaf WTA, Bloemena E, Willems SM, Meeuwis CA, Slootweg PJ, Smit LA, Merkx MAW, Takes RP, Kaanders JHAM, Groenen PJTA, Flucke UE, van Herpen CML. Boon E, et al. Oral Oncol. 2018 Jul;82:29-33. doi: 10.1016/j.oraloncology.2018.04.022. Epub 2018 May 11. Oral Oncol. 2018. PMID: 29909898 Free article.
Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands.
Boon E, van Boxtel W, Buter J, Baatenburg de Jong RJ, van Es RJJ, Bel M, Fiets E, Oosting SF, Slingerland M, Hoeben A, Tesselaar MET, Jonker MA, Flucke UE; Nationwide Network and Registry of Histopathology and Cytopathology (PALGA) Group; van der Graaf WTA, van Herpen CML. Boon E, et al. Head Neck. 2018 Mar;40(3):605-613. doi: 10.1002/hed.25035. Epub 2017 Dec 22. Head Neck. 2018. PMID: 29272069 Free PMC article.
A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands.
Boon E, Bel M, van Boxtel W, van der Graaf WTA, van Es RJJ, Eerenstein SEJ, Baatenburg de Jong RJ, van den Brekel MWM, van der Velden LA, Witjes MJH, Hoeben A, Willems SM, Bloemena E, Smit LA, Oosting SF; PALGA Group; Jonker MA, Flucke UE, van Herpen CML. Boon E, et al. Int J Cancer. 2018 Aug 15;143(4):758-766. doi: 10.1002/ijc.31353. Epub 2018 Mar 23. Int J Cancer. 2018. PMID: 29492965 Free PMC article.
Impact of chemotherapy on the outcome of osteosarcoma of the head and neck in adults.
Boon E, van der Graaf WT, Gelderblom H, Tesselaar ME, van Es RJ, Oosting SF, de Bree R, van Meerten E, Hoeben A, Smeele LE, Willems SM, Witjes MJ, Buter J, Baatenburg de Jong RJ, Flucke UE, Peer PG, Bovée JV, Van Herpen CM. Boon E, et al. Head Neck. 2017 Jan;39(1):140-146. doi: 10.1002/hed.24556. Epub 2016 Aug 10. Head Neck. 2017. PMID: 27507299 Free PMC article.
Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma.
Verhoeff SR, van Es SC, Boon E, van Helden E, Angus L, Elias SG, Oosting SF, Aarntzen EH, Brouwers AH, Kwee TC, Heskamp S, Hoekstra OS, Verheul H, van der Veldt AAM, de Vries EGE, Boerman OC, van der Graaf WTA, Oyen WJG, van Herpen CML. Verhoeff SR, et al. Among authors: boon e. Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1931-1939. doi: 10.1007/s00259-019-04358-9. Epub 2019 Jun 6. Eur J Nucl Med Mol Imaging. 2019. PMID: 31172212 Free PMC article. Clinical Trial.
RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer.
van Helden EJ, Angus L, Menke-van der Houven van Oordt CW, Heideman DAM, Boon E, van Es SC, Radema SA, van Herpen CML, de Groot DJA, de Vries EGE, Jansen MPHM, Sleijfer S, Verheul HMW. van Helden EJ, et al. Among authors: boon e. Mol Oncol. 2019 Nov;13(11):2361-2374. doi: 10.1002/1878-0261.12550. Epub 2019 Sep 30. Mol Oncol. 2019. PMID: 31350822 Free PMC article.
Decalcification of Breast Cancer Bone Metastases With EDTA Does Not Affect ER, PR, and HER2 Results.
van Es SC, van der Vegt B, Bensch F, Gerritse S, van Helden EJ, Boon E, Angus L, Overbosch J, Menke-van der Houven van Oordt CW, Verheul HM, van Herpen CML, Jager A, Oosting SF, de Vries EGE, Schröder CP. van Es SC, et al. Among authors: boon e. Am J Surg Pathol. 2019 Oct;43(10):1355-1360. doi: 10.1097/PAS.0000000000001321. Am J Surg Pathol. 2019. PMID: 31283631
[89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer.
van Helden EJ, Elias SG, Gerritse SL, van Es SC, Boon E, Huisman MC, van Grieken NCT, Dekker H, van Dongen GAMS, Vugts DJ, Boellaard R, van Herpen CML, de Vries EGE, Oyen WJG, Brouwers AH, Verheul HMW, Hoekstra OS, Menke-van der Houven van Oordt CW. van Helden EJ, et al. Among authors: boon e. Eur J Nucl Med Mol Imaging. 2020 Apr;47(4):849-859. doi: 10.1007/s00259-019-04555-6. Epub 2019 Nov 9. Eur J Nucl Med Mol Imaging. 2020. PMID: 31705176 Free PMC article.
Correction to: [89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer.
van Helden EJ, Elias SG, Gerritse SL, van Es SC, Boon E, Huisman MC, van Grieken NCT, Dekker H, van Dongen GAMS, Vugts DJ, Boellaard R, van Herpen CML, de Vries EGE, Oyen WJG, Brouwers AH, Verheul HMW, Hoekstra OS, der Houven van Oordt CWM. van Helden EJ, et al. Among authors: boon e. Eur J Nucl Med Mol Imaging. 2020 Sep;47(10):2481. doi: 10.1007/s00259-020-04908-6. Eur J Nucl Med Mol Imaging. 2020. PMID: 32535653 Free PMC article.
175 results